Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Elizabeth Zanone

Dermatology Darien, IL Physician Assistant

NPI 1982172599 CMS profile 7217731

8110 Cass Ave, Darien, IL 60561

Open in the dashboard

General payments

$13,707

402 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Elizabeth Zanone of Darien, IL is reported in the CMS Open Payments database as having received $13,707 across 402 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,496 179
2024 General $3,937 117
2023 General $1,482 61
2022 General $400 8
2021 General $1,394 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elizabeth Zanone
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Elizabeth Zanone were reported at $6,496. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Elizabeth Zanone Dermatology median Middle half National median
2019 $0 $454 $129–$1,240 $163
2020 $0 $235 $81–$756 $114
2021 $1,394 $377 $108–$1,108 $132
2022 $400 $514 $143–$1,391 $149
2023 $1,482 $607 $159–$1,674 $160
2024 $3,937 $751 $204–$1,903 $164
2025 $6,496 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Verrica Pharmaceuticals Inc. $4,676 43 payments
  2. Journey Medical Corporation $1,617 27 payments
  3. AbbVie, Inc. $1,578 58 payments
  4. Galderma Laboratories, L.P. $873 55 payments
  5. E.R. Squibb & Sons, L.L.C. $707 43 payments
  6. VYNE Pharmaceuticals Inc. $554 9 payments
  7. Lilly USA, LLC $519 19 payments
  8. Novartis Pharmaceuticals Corporation $514 29 payments
  9. Janssen Biotech, Inc. $500 21 payments
  10. Sun Pharmaceutical Industries Inc. $332 13 payments
  11. Other $1,837 85 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,428 388 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,500 5 payments
  3. Consulting Fee $500 1 payment
  4. Education $169 4 payments
  5. Travel and Lodging $111 4 payments
Products named General payments · program years 2021–2025
  1. YCANTH $4,676 43 payments
  2. SOTYKTU $707 43 payments
  3. TREMFYA $625 22 payments
  4. BOTOX $607 17 payments
  5. NEMLUVIO $601 34 payments
  6. SKYRIZI $546 24 payments
  7. COSENTYX $327 25 payments
  8. ZILXI $280 6 payments
  9. AMZEEQ $273 3 payments
  10. OLUMIANT $267 8 payments
  11. Other $3,158 171 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

530

Median for Dermatology: 534

Drug cost

$140,206

Median for Dermatology: $67,151

Branded share of claims

4.7%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cosentyx Sensoready (2 Pens) Secukinumab Brand 11 $75,829
Dupixent Pen Dupilumab Brand 14 $52,388
Tacrolimus Generic 21 $3,856
Clobetasol Propionate Generic 104 $2,820
Ketoconazole Generic 101 $1,290
Betamethasone Valerate Generic 34 $932
Triamcinolone Acetonide Generic 86 $926
Mometasone Furoate Generic 65 $790
Gentamicin Sulfate Generic 16 $691
Doxycycline Hyclate Generic 22 $261

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
YCANTH
$2,043 — —
SOTYKTU
$491 — —
SKYRIZI
$191 — —
TREMFYA
$177 — —
COSENTYX
$133 11 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

402 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record